Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2026-02-28 @ 11:29 PM
Study NCT ID:
NCT04632056
Status:
COMPLETED
Last Update Posted:
2023-11-14
First Post:
2020-11-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neovascular Age-related Macular Degeneration | View |